153 related articles for article (PubMed ID: 34051575)
1. GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway.
Liu C; Wang W; Lin P; Xie H; Jiang S; Jia H; Li R; Wang N; Yu X
Biochem Biophys Res Commun; 2021 Jul; 562():119-126. PubMed ID: 34051575
[TBL] [Abstract][Full Text] [Related]
2. Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer.
Gravina GL; Marampon F; Sanità P; Mancini A; Colapietro A; Scarsella L; Jitariuc A; Biordi L; Ficorella C; Festuccia C
Oncol Rep; 2016 Jul; 36(1):125-30. PubMed ID: 27222100
[TBL] [Abstract][Full Text] [Related]
3. β
Zhang M; Wang Q; Sun X; Yin Q; Chen J; Xu L; Xu C
Prostate; 2020 Nov; 80(15):1328-1340. PubMed ID: 32894788
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA‑15b‑5p exerts its tumor repressive role via targeting GDI2: A novel insight into the pathogenesis of thyroid carcinoma.
Zou J; Qian J; Fu H; Yin F; Zhao W; Xu L
Mol Med Rep; 2020 Oct; 22(4):2723-2732. PubMed ID: 32945458
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of PER3 reverses paclitaxel resistance of prostate cancer cells by inhibiting the Notch pathway.
Cai DW; Chen D; Sun SP; Liu ZJ; Liu F; Xian SZ; Wu PS; Kong GQ
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2572-2579. PubMed ID: 29771413
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
8. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
10. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
Li B; Jin X; Meng H; Hu B; Zhang T; Yu J; Chen S; Guo X; Wang W; Jiang W; Wang J
Oncotarget; 2017 Jul; 8(29):47849-47860. PubMed ID: 28599307
[TBL] [Abstract][Full Text] [Related]
11. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death.
Pflug B; Djakiew D
Mol Carcinog; 1998 Oct; 23(2):106-14. PubMed ID: 9808164
[TBL] [Abstract][Full Text] [Related]
12. HES6 promotes prostate cancer aggressiveness independently of Notch signalling.
Carvalho FL; Marchionni L; Gupta A; Kummangal BA; Schaeffer EM; Ross AE; Berman DM
J Cell Mol Med; 2015 Jul; 19(7):1624-36. PubMed ID: 25864518
[TBL] [Abstract][Full Text] [Related]
13. CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel.
Aghajani M; Mokhtarzadeh A; Aghebati-Maleki L; Mansoori B; Mohammadi A; Safaei S; Asadzadeh Z; Hajiasgharzadeh K; Khaze Shahgoli V; Baradaran B
Mol Biol Rep; 2020 May; 47(5):3691-3703. PubMed ID: 32246247
[TBL] [Abstract][Full Text] [Related]
14. Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.
Li D; Zhao LN; Zheng XL; Lin P; Lin F; Li Y; Zou HF; Cui RJ; Chen H; Yu XG
Mol Med Rep; 2014 Dec; 10(6):3169-76. PubMed ID: 25310235
[TBL] [Abstract][Full Text] [Related]
15. Activator of G protein signaling 3 modulates prostate tumor development and progression.
Adekoya TO; Smith N; Aladeniyi T; Blumer JB; Chen XL; Richardson RM
Carcinogenesis; 2019 Dec; 40(12):1504-1513. PubMed ID: 31215992
[TBL] [Abstract][Full Text] [Related]
16. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
Xue YN; Yu BB; Liu YN; Guo R; Li JL; Zhang LC; Su J; Sun LK; Li Y
Prostate; 2019 May; 79(6):647-656. PubMed ID: 30714183
[TBL] [Abstract][Full Text] [Related]
17. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway.
Wang D; Lu G; Shao Y; Xu D
Biomed Pharmacother; 2018 Mar; 99():334-339. PubMed ID: 29353209
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
[TBL] [Abstract][Full Text] [Related]
19. Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway.
Xu F; Gu J; Lu C; Mao W; Wang L; Zhu Q; Liu Z; Chu Y; Liu R; Ge D
Int J Biol Sci; 2019; 15(1):127-137. PubMed ID: 30662353
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2.
Zhou YJ; Yang HQ; Xia W; Cui L; Xu RF; Lu H; Xue Z; Zhang B; Tian ZN; Cao YJ; Xing ZY; Yin S; He XZ
Life Sci; 2017 Dec; 190():7-14. PubMed ID: 28943214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
